ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

ACELRX PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex_127679.htm EXHIBIT 99.1 ex_127668.htm Exhibit 99.1       News Release       AcelRx announces FDA approval of DSUVIA™   ● DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings   ● First and only sufentanil sublingual tablet approved for acute pain in healthcare settings   ● DSUVIA U.S. launch expected in the first quarter of 2019   ● Conference-call scheduled for Monday,…
To view the full exhibit click here

About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.